Maite Verreault
Overview
Explore the profile of Maite Verreault including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
37
Citations
931
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
21.
Rosenberg S, Simeonova I, Bielle F, Verreault M, Bance B, Le Roux I, et al.
Nat Commun
. 2018 Jun;
9(1):2371.
PMID: 29915258
Chordoid glioma (ChG) is a characteristic, slow growing, and well-circumscribed diencephalic tumor, whose mutational landscape is unknown. Here we report the analysis of 16 ChG by whole-exome and RNA-sequencing. We...
22.
Drean A, Rosenberg S, Lejeune F, Goli L, Nadaradjane A, Guehennec J, et al.
J Neurooncol
. 2018 Mar;
138(3):487.
PMID: 29549621
The names of authors Marc Sanson and Jean-Yves Delattre were incorrectly presented in the initial online publication. The original article has been corrected.
23.
Drean A, Rosenberg S, Lejeune F, Goli L, Nadaradjane A, Guehennec J, et al.
J Neurooncol
. 2018 Mar;
138(3):479-486.
PMID: 29520610
ATP-binding cassette transporters (ABC transporters) regulate traffic of multiple compounds, including chemotherapeutic agents, through biological membranes. They are expressed by multiple cell types and have been implicated in the drug...
24.
El-Habr E, Dubois L, Burel-Vandenbos F, Bogeas A, Lipecka J, Turchi L, et al.
Acta Neuropathol
. 2016 Dec;
133(4):645-660.
PMID: 28032215
Cell populations with differing proliferative, stem-like and tumorigenic states co-exist in most tumors and especially malignant gliomas. Whether metabolic variations can drive this heterogeneity by controlling dynamic changes in cell...
25.
Rosenberg S, Verreault M, Schmitt C, Guegan J, Guehennec J, Levasseur C, et al.
Neuro Oncol
. 2016 Aug;
19(2):219-228.
PMID: 27571888
Background: Glioblastoma (GBM) is the deadliest primary brain cancer in adults. Emerging innovative therapies hold promise for personalized cancer treatment. Improving therapeutic options depends on research relying on relevant preclinical...
26.
Drean A, Goldwirt L, Verreault M, Canney M, Schmitt C, Guehennec J, et al.
Expert Rev Neurother
. 2016 Jun;
16(11):1285-1300.
PMID: 27310463
Glioblastomas (GBM) are the most common and aggressive primary malignant brain tumors in adults. The blood brain barrier (BBB) is a major limitation reducing efficacy of anti-cancer drugs in the...
27.
Preclinical Efficacy of the MDM2 Inhibitor RG7112 in MDM2-Amplified and TP53 Wild-type Glioblastomas
Verreault M, Schmitt C, Goldwirt L, Pelton K, Haidar S, Levasseur C, et al.
Clin Cancer Res
. 2015 Oct;
22(5):1185-96.
PMID: 26482041
Purpose: p53 pathway alterations are key molecular events in glioblastoma (GBM). MDM2 inhibitors increase expression and stability of p53 and are presumed to be most efficacious in patients with TP53...
28.
Verreault M, Weppler S, Stegeman A, Warburton C, Strutt D, Masin D, et al.
PLoS One
. 2013 Apr;
8(3):e59597.
PMID: 23555046
The PI3K/AKT/mTOR pathway is commonly over activated in glioblastoma (GBM), and Rictor was shown to be an important regulator downstream of this pathway. EGFR overexpression is also frequently found in...
29.
Verreault M, Delattre J, Idbaih A
Med Sci (Paris)
. 2012 Oct;
28(10):813-6.
PMID: 23067408
No abstract available.
30.
Lee C, Fotovati A, Triscott J, Chen J, Venugopal C, Singhal A, et al.
Stem Cells
. 2012 Mar;
30(6):1064-75.
PMID: 22415968
Glioblastoma multiforme (GBM) ranks among the deadliest types of cancer and given these new therapies are urgently needed. To identify molecular targets, we queried a microarray profiling 467 human GBMs...